{"disease":{"id":"persistent-or-chronic-immune-thrombocytopenia-itp","name":"persistent or chronic immune thrombocytopenia itp"},"drugs":{"marketed":[{"drug_id":"rilzabrutinib","indication_name":"persistent or chronic immune thrombocytopenia (ITP)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Wayrilz","generic_name":"RILZABRUTINIB","company_name":"Genzyme Corp","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":48,"revenue":null,"mechanism":"Wayrilz works by blocking a specific enzyme that helps platelet-destroying immune cells function."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}